4 December 2017 - Patients saw a clinically significant improvement in the condition of their skin and reduction in itch within the first four months of biweekly treatment.

Sanofi Genzyme announced today the Health Canada approval for Dupixent (dupilumab) for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. This is the first biologic therapy in Canada to target the root cause of atopic dermatitis.

The approval of Dupixent is based on data from the global LIBERTY AD clinical program, which included three randomised Phase 3 pivotal trials known as SOLO 1, SOLO 2 and CHRONOS (enrolled 2,119 total adult patients with inadequately controlled moderate-to-severe AD, (including 274 Canadians). SOLO 1 and SOLO 2 examined the use of Dupixent alone, while CHRONOS looked at the use of Dupixent with topical corticosteroids in patients. In all three studies, Dupixent alone or with topical corticosteroids provided rapid and sustained improvement in lesion extent and severity, itch intensity and health-related quality of life measures, specifically.

Read Sanofi Genzyme press release